Stéphanie Forté: Gene Therapy in Sickle Cell Disease from Molecular Advances to Clinical Care
Stéphanie Forté, Principal Researcher at the Innovation Hub at the CHUM Research Center (CRCHUM), shared a post on LinkedIn about a recent article she and her colleagues co-authored, adding:
“Very excited to share our new review on gene therapies in sickle cell disease, published in Cells:
The Journey of Gene Therapy in Sickle Cell Disease: How Molecular Advances Meet Clinical Care
Advances in gene therapy are ushering in a new era of hope for people living with sickle cell disease.
Our hope now is that these innovations become more equitably accessible worldwide.
The RED Network (Erythrocytes and Sickle Cell Network) continues to pursue this goal by strengthening international collaborations, patient registries, andclinical research in order to accelerate meaningful global progress for patients.”
Title: The Journey of Gene Therapy in Sickle Cell Disease: How Molecular Advances Meet Clinical Care
Authors: Magalie Tardif, Manon Saby, Stéphanie Forté, Thomas Pincez
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 7, 2026, 06:19Simone Schoenwaelder: Women Are 25% More Likely to Have Their Stroke Misdiagnosed and Here’s Why
-
Jul 7, 2026, 06:12Dhiraj Bhatia: Extremely Happy to Share Our Review on DNA Nanotechnology in Stroke Repair
-
Jul 7, 2026, 06:04Brian A Beh: An Open Letter to Lisa Murphy Honouring the 30 Years of the Stroke Foundation’s Dedication
-
Jul 7, 2026, 05:55Alan Nurden: A Landmark Review Comparing Hemophilia and Hereditary Angioedema
-
Jul 7, 2026, 05:40Andrew Agwunobi: UConn Health is Proud to Advance Stroke Rehabilitation for Veterans
-
Jul 6, 2026, 22:54Louise St. Germain Bannon: I Wanted to Recognize the Incredible Staff Behind ISTH 2026
-
Jul 6, 2026, 21:46Armghan Ans: UPMC Washington Stroke Program Earns AHA Gold Plus Award for 16th Consecutive Year
-
Jul 6, 2026, 20:31Manik Madaan: Master Transfusion Reactions for USMLE In Less Than 60 Seconds
-
Jul 6, 2026, 19:25Ambreen Kashif: Highlighting the Impact of Temporary Donor Deferrals on Donor Retention